These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 26617215)

  • 1. New therapeutic opportunities for 5-HT2C receptor ligands in neuropsychiatric disorders.
    Di Giovanni G; De Deurwaerdère P
    Pharmacol Ther; 2016 Jan; 157():125-62. PubMed ID: 26617215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A short history of the 5-HT
    Palacios JM; Pazos A; Hoyer D
    Psychopharmacology (Berl); 2017 May; 234(9-10):1395-1418. PubMed ID: 28265714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple controls exerted by 5-HT2C receptors upon basal ganglia function: from physiology to pathophysiology.
    De Deurwaerdère P; Lagière M; Bosc M; Navailles S
    Exp Brain Res; 2013 Oct; 230(4):477-511. PubMed ID: 23615975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. We Need 2C but Not 2B: Developing Serotonin 2C (5-HT2C) Receptor Agonists for the Treatment of CNS Disorders.
    Cheng J; Kozikowski AP
    ChemMedChem; 2015 Dec; 10(12):1963-7. PubMed ID: 26507582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the 5-HT2C Receptor in Biological Context and the Current State of 5-HT2C Receptor Ligand Development.
    Wold EA; Wild CT; Cunningham KA; Zhou J
    Curr Top Med Chem; 2019; 19(16):1381-1398. PubMed ID: 31288724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-HT2C receptors in psychiatric disorders: A review.
    Chagraoui A; Thibaut F; Skiba M; Thuillez C; Bourin M
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Apr; 66():120-135. PubMed ID: 26739950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serotonin/dopamine interaction--focus on 5-HT2C receptor, a new target of psychotropic drugs.
    Di Giovanni G; Di Matteo V; Esposito E
    Indian J Exp Biol; 2002 Dec; 40(12):1344-52. PubMed ID: 12974395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Central serotonin2C receptor: from physiology to pathology.
    Di Giovanni G; Di Matteo V; Pierucci M; Benigno A; Esposito E
    Curr Top Med Chem; 2006; 6(18):1909-25. PubMed ID: 17017966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-HT2C receptor modulators: a patent survey.
    Lee J; Jung ME; Lee J
    Expert Opin Ther Pat; 2010 Nov; 20(11):1429-55. PubMed ID: 20849206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-HT2C receptor desensitization moderates anxiety in 5-HTT deficient mice: from behavioral to cellular evidence.
    Martin CB; Martin VS; Trigo JM; Chevarin C; Maldonado R; Fink LH; Cunningham KA; Hamon M; Lanfumey L; Mongeau R
    Int J Neuropsychopharmacol; 2014 Oct; 18(3):. PubMed ID: 25522398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on the neuroendocrine role of serotonin.
    Jørgensen HS
    Dan Med Bull; 2007 Nov; 54(4):266-88. PubMed ID: 18208678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the Serotonin 5-HT7 Receptor in the Search for Treatments for CNS Disorders: Rationale and Progress to Date.
    Nikiforuk A
    CNS Drugs; 2015 Apr; 29(4):265-75. PubMed ID: 25721336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospects for serotonin 5-HT2R pharmacotherapy in psychostimulant abuse.
    Bubar MJ; Cunningham KA
    Prog Brain Res; 2008; 172():319-46. PubMed ID: 18772040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Potential PET Radiotracer for the 5-HT
    Kim J; Moon BS; Lee BC; Lee HY; Kim HJ; Choo H; Pae AN; Cho YS; Min SJ
    ACS Chem Neurosci; 2017 May; 8(5):996-1003. PubMed ID: 28194935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiological relevance of constitutive activity of 5-HT2A and 5-HT2C receptors.
    Berg KA; Harvey JA; Spampinato U; Clarke WP
    Trends Pharmacol Sci; 2005 Dec; 26(12):625-30. PubMed ID: 16269190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mCPP-induced hyperactivity in 5-HT2C receptor mutant mice is mediated by activation of multiple 5-HT receptor subtypes.
    Dalton GL; Lee MD; Kennett GA; Dourish CT; Clifton PG
    Neuropharmacology; 2004 Apr; 46(5):663-71. PubMed ID: 14996544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors.
    Tecott LH; Sun LM; Akana SF; Strack AM; Lowenstein DH; Dallman MF; Julius D
    Nature; 1995 Apr; 374(6522):542-6. PubMed ID: 7700379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuropeptides and neuropeptide receptors: drug targets, and peptide and non-peptide ligands: a tribute to Prof. Dieter Seebach.
    Hoyer D; Bartfai T
    Chem Biodivers; 2012 Nov; 9(11):2367-87. PubMed ID: 23161624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status of inverse agonism at serotonin2A (5-HT2A) and 5-HT2C receptors.
    Aloyo VJ; Berg KA; Spampinato U; Clarke WP; Harvey JA
    Pharmacol Ther; 2009 Feb; 121(2):160-73. PubMed ID: 19109993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy.
    Schaerlinger B; Hickel P; Etienne N; Guesnier L; Maroteaux L
    Br J Pharmacol; 2003 Sep; 140(2):277-84. PubMed ID: 12970106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.